Questa pagina è stata tradotta automaticamente e l'accuratezza della traduzione non è garantita. Si prega di fare riferimento al Versione inglese per un testo di partenza.

Siplizumab nel T1DM (DESIGNATE)

Studio sulla determinazione della dose guidata dalla firma del fenotipo delle cellule AT con siplizumab nel diabete mellito di tipo 1 (ITN095AI)

This is a multicenter, Phase Ib, open-label, siplizumab dose-finding study in individuals aged 8-45 years with a Type 1 diabetes mellitus (T1DM) diagnosis. within 18 months of V0. Participants will be randomized 1:1:1:1 to one of four possible siplizumab dosing arms. All dosing arms will receive weekly siplizumab doses for a total of 12 weeks. After the completion of treatment, participants will undergo follow-up visits at weeks 12, 24, 36 and 52 which include longitudinal MMTTs. If indicated, participants will enter into long-term safety monitoring for up to an additional 48 weeks. Blood samples for mechanistic analyses will be obtained during the treatment phase and thereafter. Adults aged 18- 45 will be enrolled initially at the study sites.

The primary objective is to identify a safe, metabolically favorable, dosing regimen for siplizumab in patients with type 1 diabetes that induces changes in T cell phenotypes observed with alefacept therapy in new-onset T1DM.

The secondary objectives are to:

  1. Assess the safety profile of siplizumab in recently diagnosed T1DM.
  2. Assess the effects of siplizumab on residual beta cell function in recently diagnosed T1DM participants.

Panoramica dello studio

Stato

Terminato

Condizioni

Intervento / Trattamento

Tipo di studio

Interventistico

Iscrizione (Effettivo)

8

Fase

  • Fase 2
  • Fase 1

Contatti e Sedi

Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.

Luoghi di studio

    • Colorado
      • Aurora, Colorado, Stati Uniti, 80045
        • University of Colorado School of Medicine: Barbara Davis Center for Diabetes
    • Iowa
      • Iowa City, Iowa, Stati Uniti, 52242
        • University of Iowa Children's Hospital: Department of Pediatrics, Pediatric Endocrinology and Diabetes
    • New York
      • New York, New York, Stati Uniti, 10032
        • Columbia University Medical Center: Naomi Berrie Diabetes Center
    • Texas
      • Dallas, Texas, Stati Uniti, 75390
        • University of Texas Southwestern Medical Center: Department of Internal Medicine, Division of Endocrinology
    • Washington
      • Seattle, Washington, Stati Uniti, 98101
        • Benaroya Research Institute at Virginia Mason: Diabetes Research Program

Criteri di partecipazione

I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.

Criteri di ammissibilità

Età idonea allo studio

Da 8 anni a 45 anni (Bambino, Adulto)

Accetta volontari sani

No

Sessi ammissibili allo studio

Tutto

Descrizione

Inclusion Criteria:

  1. Ability to provide informed consent (parental permission and informed assent of minor, if applicable).

  2. Male or female between 8 to 45 years of age.

  3. Diagnosis of T1DM within 18 months (550 days) of enrollment (V0).

  4. Positive for at least one diabetes-related autoantibody, including:

    1. Glutamate decarboxylase (GAD-65),
    2. Insulin, if obtained within 10 days of the onset of exogenous insulin therapy,
    3. Insulinoma antigen-2 (IA-2), or
    4. Zinc transporter-8 (ZnT8).
  5. Peak stimulated C-peptide level > 0.15 nmol/L following a MMTT conducted ≥ 21 days from diagnosis and within 37 days of enrollment (V0).

  6. Completion of a SARS-CoV-2 vaccination, according to current CDC recommendations and FDA approval(s) or emergency use authorization(s). If the participant requires administration of vaccine(s) to meet eligibility requirements, they must complete the vaccination series at least 2 weeks prior to enrollment (V0).

Exclusion Criteria:

  1. 1. Use of investigational drugs within 24 weeks of participation with the exception of any vaccine for the prevention of SARS-CoV-2 infection and emergency use authorization medications for treating SARS-CoV-2.

  2. Severe reaction or anaphylaxis to humanized monoclonal antibodies.

  3. Inability to complete a mixed meal tolerance test:

    1. History of significant allergy (e.g., anaphylaxis) to milk or soy proteins.
    2. Inability to disable hybrid closed loop system.
  4. History of recent (within 180 days of V0) or ongoing uncontrolled bacterial, viral, fungal or other opportunistic infections, including:

    1. Human immunodeficiency virus (HIV),
    2. Current or prior infection with hepatitis B (HBV), as indicated by positive HBsAg or positive HBcAb,
    3. Current or prior hepatitis C (HCV), unless treated with anti-viral therapy with achievement of a sustained virologic response (undetectable viral load 12 weeks after cessation of therapy),
    4. Positive QuantiFERON-TB Gold or QuantiFERON-TB Gold Plus tests. PPD or T-SPOT®.TB may be substituted for the QuantiFERON-TB Gold or QuantiFERON-TB Gold Plus tests,
    5. Active infection with EBV as detected by PCR or serology at the screening visit (V-1),
    6. Active infection with cytomegalovirus (CMV) as detected by PCR or serology at the screening visit (V-1),
  5. Positive molecular testing of SARS-CoV-2 within 30 days of V-1.

  6. Any of the following laboratory abnormalities confirmed by repeat tests at least 1 week apart:

    1. White blood count (WBC) < 3 x 103/μL;,
    2. CD 3+ CD4+, T cell count below the lower limit of normal,
    3. Platelet count < 150,000 /μL,
    4. Hemoglobin < 10 g/dL,
    5. ALT ≥ 2x upper limit of normal (ULN) or
    6. AST ≥ 2x ULN
    7. Serum creatinine >1.5x ULN in adults or >ULN in pediatrics.
    8. Absolute lymphocyte count (ALC) below the LLN.
  7. Prior or current treatment that is known to alter the natural history of T1DM or immunologic status, including high dose inhaled, extensive topical or systemic glucocorticoids.

  8. Current or prior (within last 14 days of the V-1 MMTT) use of any medication known to influence glucose tolerance (e.g., atypical antipsychotics, diphenylhydantoin, thiazide, or other potassium-depleting diuretics, β-adrenergic blockers, niacin).

  9. Current or prior (within the last 30 days of the V-1 MMTT) use of non-insulin medications to treat insulin resistance or elevated glucose levels.

  10. Previous or current diagnosis of malignancy.

  11. History of bone marrow transplantation, solid organ transplantation, or primary immunodeficiencies.

  12. History or diagnoses of other autoimmune diseases with the exception of stable thyroid or celiac disease.

  13. History of significant cardiovascular disease.

  14. Vaccination with a live attenuated vaccine (e.g., varicella, measles, mumps, rubella, cold-attenuated intranasal influenza vaccine, bacillus Calmette- Guérin, and smallpox) within 30 days of V0.

  15. Women of child-bearing potential who are unwilling to use a medically acceptable form of contraception from 14 days prior to V0 until study Week 52.

  16. Women who are pregnant, lactating, or planning on pregnancy during the study.

  17. Current, diagnosed mental illness (e.g., severe depression), current diagnosed or self-reported drug, or alcohol abuse that, in the opinion of the investigator, would interfere with the participant's ability to comply with study requirements.

  18. Past or current medical problems or findings from physical examination or laboratory testing that are not listed above, which, in the opinion of the investigator, may pose additional risks from participation in the study, may interfere with the participant's ability to comply with study requirements or that may impact the quality or interpretation of the data obtained from the study.

Piano di studio

Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.

Come è strutturato lo studio?

Dettagli di progettazione

  • Scopo principale: Trattamento
  • Assegnazione: Randomizzato
  • Modello interventistico: Assegnazione parallela
  • Mascheramento: Nessuno (etichetta aperta)

Armi e interventi

Gruppo di partecipanti / Arm
Intervento / Trattamento
Sperimentale: Adults with T1D 0.08 mg/kg SQ dose

Cohort 1 Group1: 0.08 mg/kg SQ dose for a total of 12 weeks

Weekly siplizumab doses for a total of 12 weeks

Altri nomi:
  • TCD 601
Sperimentale: Adults with T1D 0.12 mg/kg SQ dose

Cohort 1 Group 2: 0.12 mg/kg SQ dose for a total of 12 weeks

Weekly siplizumab doses for a total of 12 weeks

Altri nomi:
  • TCD 601
Sperimentale: Adults with T1D 0.18 mg/kg SQ dose

Cohort 1 Group 3:0.18 mg/kg SQ dose for a total of 12 weeks

Weekly siplizumab doses for a total of 12 weeks

Altri nomi:
  • TCD 601
Sperimentale: Adults with T1D 0.22 mg/kg SQ dose

Cohort 1 Group 4: 0.22 mg/kg SQ dose for a total of 12 weeks

Weekly siplizumab doses for a total of 12 weeks

Altri nomi:
  • TCD 601
Sperimentale: Children with T1D 0.08 mg/kg SQ dose

Cohort 2 Group 1:0.08 mg/kg SQ dose for a total of 12 weeks

Weekly siplizumab doses for a total of 12 weeks

Altri nomi:
  • TCD 601
Sperimentale: Children with T1D 0.12 mg/kg SQ dose

Cohort 2 Group 2:0.12 mg/kg SQ dose for a total of 12 weeks

Weekly siplizumab doses for a total of 12 weeks

Altri nomi:
  • TCD 601
Sperimentale: Children with T1D 0.18 mg/kg SQ dose

Cohort 2 Group 3: 0.18 mg/kg SQ dose for a total of 12 weeks

Weekly siplizumab doses for a total of 12 weeks

Altri nomi:
  • TCD 601
Sperimentale: Children with T1D 0.22 mg/kg SQ dose

Cohort 2 Group 4: 0.22 mg/kg SQ dose for a total of 12 weeks

Weekly siplizumab doses for a total of 12 weeks

Altri nomi:
  • TCD 601

Cosa sta misurando lo studio?

Misure di risultato primarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Number of Participants With a T Cell Phenotype Signature Response
Lasso di tempo: Week 0 to Week 12

A participant is defined as achieving a T Cell phenotype signature response if the participant experiences both a 75% increase or greater from baseline in the CD4 Treg/Tem ratio in blood and a 20% increase or greater from baseline in PD1+TIGIT+ frequency within circulating CD4 Tem. The two criteria will be evaluated at weeks 2, 4, 8, and 12. Both criteria do not need to be achieved at the same time point.

Week 0 to Week 12

Misure di risultato secondarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Frequency of Adverse Events (AEs) in All Siplizumab Dosing Arms
Lasso di tempo: From week 0 to week 100

AE will include any untoward medical occurrence associated with siplizumab administration or any study-mandated procedure. A treatment-emergent adverse event (TEAE) is defined as in increase in grade from baseline or from the last post-baseline value that doesn't meet grading criteria.

From week 0 to week 100
Mixed Meal Tolerance Test (MMTT)-Stimulated Mean 2-hour C-peptide AUC
Lasso di tempo: At Weeks 12, 24, 36, 52

C-peptide is released by the pancreas into the bloodstream in equal amounts to insulin and reflects how much insulin pancreatic beta cells are making. The mixed meal tolerance test (MMTT) was performed in the morning, and blood samples for C-peptide were collected at baseline (pre-meal) and various minutes post-meal at each visit and analyzed by a central laboratory. C-peptide area under the curve (AUC) was calculated using the trapezoidal rule over the 2-hour time period. Larger numbers are better in these AUC results: more insulin being produced reflects less severe disease. The mean 2-hour C-peptide AUC, measured in nmol/L, is computed by dividing the total AUC by the length of the MMTT (e.g. 120 minutes).

At Weeks 12, 24, 36, 52
Insulin Use (U/kg/Day)
Lasso di tempo: At Weeks 6, 12, 24, 36 and 52.

Measured as U/kg body weight/day; participants recorded the type and amount of insulin they have used during the 5-day period immediately preceding the beginning of treatment, middle of treatment, end of treatment, and at all follow-up visits

At Weeks 6, 12, 24, 36 and 52.

Collaboratori e investigatori

Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.

Sponsor

Investigatori

  • Cattedra di studio: Stephen Gitelman, M.D., University of California San Francisco, School of Medicine: Diabetes Center

Pubblicazioni e link utili

La persona responsabile dell'inserimento delle informazioni sullo studio fornisce volontariamente queste pubblicazioni. Questi possono riguardare qualsiasi cosa relativa allo studio.

Studiare le date dei record

Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.

Studia le date principali

Inizio studio (Effettivo)

18 maggio 2023

Completamento primario (Effettivo)

14 maggio 2025

Completamento dello studio (Effettivo)

20 ottobre 2025

Date di iscrizione allo studio

Primo inviato

19 settembre 2022

Primo inviato che soddisfa i criteri di controllo qualità

6 ottobre 2022

Primo Inserito (Effettivo)

10 ottobre 2022

Aggiornamenti dei record di studio

Ultimo aggiornamento pubblicato (Effettivo)

13 novembre 2026

Ultimo aggiornamento inviato che soddisfa i criteri QC

21 ottobre 2026

Ultimo verificato

1 settembre 2026

Maggiori informazioni

Termini relativi a questo studio

Altri numeri di identificazione dello studio

  • DAIT ITN095AI

Piano per i dati dei singoli partecipanti (IPD)

Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?

SÌ

Descrizione del piano IPD

Immunology Database and Analysis Portal (ImmPort), a long-term archive of clinical and mechanistic data from DAIT-funded grants and contracts.

Periodo di condivisione IPD

On average, within 24 months after database lock for the trial.

Criteri di accesso alla condivisione IPD

Open access.

Informazioni su farmaci e dispositivi, documenti di studio

Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti

Sì

Studia un dispositivo regolamentato dalla FDA degli Stati Uniti

No

Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .